Meteora Capital’s Coeptis Therapeutics Warrants COEPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.2K | Hold |
114,873
| – | – | ﹤0.01% | 411 |
|
|
2026
Q1 | $1.33K | Buy |
+114,873
| New | +$1.38K | ﹤0.01% | 351 |
|
|
2025
Q4 | – | Sell |
-114,873
| Closed | -$3.02K | – | 421 |
|
|
2025
Q3 | $3.02K | Sell |
114,873
-135,127
| -54% | -$3.57K | ﹤0.01% | 277 |
|
|
2025
Q2 | $6.5K | Sell |
250,000
-2,229
| -0.9% | -$49 | ﹤0.01% | 160 |
|
|
2025
Q1 | $2.72K | Sell |
252,229
-174,844
| -41% | -$4.58K | ﹤0.01% | 142 |
|
|
2024
Q4 | $9.39K | Sell |
427,073
-586,919
| -58% | -$14K | ﹤0.01% | 131 |
|
|
2024
Q3 | $15.2K | Sell |
1,013,992
-183,082
| -15% | -$3.66K | ﹤0.01% | 150 |
|
|
2024
Q2 | $27K | Hold |
1,197,074
| – | – | ﹤0.01% | 179 |
|
|
2024
Q1 | $30.5K | Buy |
1,197,074
+1,048,631
| +706% | +$43K | 0.01% | 179 |
|
|
2023
Q4 | $4.6K | Hold |
148,443
| – | – | ﹤0.01% | 246 |
|
|
2023
Q3 | $3.35K | Hold |
148,443
| – | – | ﹤0.01% | 291 |
|
|
2023
Q2 | $11.1K | Hold |
148,443
| – | – | ﹤0.01% | 248 |
|
|
2023
Q1 | $21.9K | Sell |
148,443
-143,490
| -49% | -$18.5K | ﹤0.01% | 277 |
|
|
2022
Q4 | $29.2K | Buy |
+291,933
| New | +$19.5K | 0.01% | 212 |
|
|
2022
Q3 | – | Sell |
-388,443
| Closed | -$18K | – | 402 |
|
|
2022
Q2 | $18K | Buy |
+388,443
| New | +$29.2K | ﹤0.01% | 340 |
|
Other funds holding COEPW
Meteora Capital's COEPW Position: Q2 2026 in Review
Meteora Capital held its Coeptis Therapeutics Warrants (COEPW) position steady in Q2 2026 at 114,873 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #411.
Meteora Capital first reported a position in COEPW in Q2 2022 and has held it in 15 quarters since. The position peaked at $30.5K in Q1 2024. 3 funds tracked by Wall St. Rank hold COEPW as of Q2 2026.
- Meteora Capital held 114,873 shares of Coeptis Therapeutics Warrants worth $1.2K as of Q2 2026.
- Meteora Capital left its Coeptis Therapeutics Warrants share count unchanged in Q2 2026.
- Coeptis Therapeutics Warrants made up ﹤0.01% of Meteora Capital's portfolio in Q2 2026, its #411 holding.
- Meteora Capital first reported a position in Coeptis Therapeutics Warrants in Q2 2022 and has held it in 15 quarters since.
- Meteora Capital's Coeptis Therapeutics Warrants position peaked at $30.5K in Q1 2024.
- 3 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q2 2026.
Based on Meteora Capital's 13F filing for Q2 2026, filed 14 Aug 2026.